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Abstract
This study aimed to identify the intracellular signaling pathway in angiotensin II (Ang II)-induced upregulation of
plasminogen activator inhibitor type 1 (PAI-1) mRNA expression in cultured rat glomerular mesangial cells, and to examine
the interaction between Ang II and TGF-L signaling. Ang II-induced upregulation of PAI-1 mRNA expression was
prevented by a protein kinase C (PKC) inhibitor, bisindorylmaleimide I. While phorbol 12-myristate 13-acetate (PMA)
upregulated the PAI-1 mRNA expression, a calcium ionophore, ionomycin, had little effect. Mesangial cells pretreated with
PMA for 24 h to downregulate PKC demonstrated attenuated response to Ang II. A protein tyrosine kinase inhibitor,
genistein, completely blocked both Ang II- and PMA-induced PAI-1 mRNA expression. Transforming growth factor-L1
(TGF-L1) alone induced the expression, and in the presence of Ang II, TGF-L1 superinduced PAI-1 mRNA expression to a
higher extent. Both bisindorylmaleimide I and genistein suppressed the Ang II plus TGF-L1-induced PAI-1 mRNA
upregulation to the basal level, while downregulation of PKC attenuated the synergistic upregulation of PAI-1 mRNA
expression to the level comparable to TGF-L1 alone. These data suggest that, in rat mesangial cells, (1) PKC and protein
tyrosine kinase(s) are involved in the Ang II signaling cascade, (2) protein tyrosine kinase(s) works downstream from PKC in
the cascade, and (3) there is an interaction between the Ang II and TGF-L signal pathways downstream from PKC. In in vivo
settings, local activation of renin-angiotensin and TGF-L systems in the glomeruli may synergistically augment PAI-1
expression, promote mesangial matrix accumulation and progression of glomerular injury. ß 1999 Elsevier Science B.V.
All rights reserved.
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1. Introduction
Angiotensin II (Ang II), an octapeptide, is a major
e¡ector molecule in the renin-angiotensin system.
Ang II regulates systemic blood pressure both by a
direct vasopressor e¡ect and by the induction of oth-
er vasoactive compounds. In addition, recent ¢ndings
revealed that it promotes cellular proliferation and
extracellular matrix accumulation in vascular con-
tractile cells such as vascular smooth muscle cells
0167-4889 / 99 / $ ^ see front matter ß 1999 Elsevier Science B.V. All rights reserved.
PII: S 0 1 6 7 - 4 8 8 9 ( 9 9 ) 0 0 0 1 4 - 2
* Corresponding author. Fax: +81 (3) 33627340;
E-mail : ct005@mb.infoweb.ne.jp
BBAMCR 14449 26-3-99
Biochimica et Biophysica Acta 1449 (1999) 217^226
[1,2] and glomerular mesangial cells [3,4]. These ef-
fects of Ang II have been proposed to participate in
the development of cardiovascular and renal diseases
including glomerulosclerosis [5,6]. Considerable in-
terests have been directed to determine the factors
involved in the Ang II-induced signal pathway that
leads to cellular proliferation and upregulation of
extracellular matrix formation.
There are at least two di¡erent Ang II receptors,
type 1 (AT1) and type 2 (AT2) [7]. They are charac-
teristic G-protein-coupled receptors with seven trans-
membrane domains. Most of the known physiologi-
cal actions of Ang II are mediated by the AT1
receptor. Activation of AT1 stimulates phosphatidyl
inositol hydrolysis, resulting in an increase in intra-
cellular Ca2 concentration and protein kinase C
(PKC) activation [8,9]. Ang II also stimulates tyro-
sine phosphorylation of several factors such as phos-
pholipase C-Q1 [10], mitogen-activated protein kin-
ases (MAPKs) [11], and Janus kinases (JAK) [12]
which play a role in signal transduction pathways
that lead to cellular proliferation and/or di¡erentia-
tion.
In rat glomerular mesangial cells, Ang II stimu-
lates production of mesangial matrix components.
Recent ¢ndings demonstrate that plasmin is a major
regulator of mesangial matrix turnover [13]. Plasmin
generation is regulated by a balance between plas-
minogen activator (PA) and plasminogen activator
inhibitors (PAI). Glomeruli isolated from animal
models of proliferative glomerulonephritis show
increased plasminogen activator inhibitor type 1
(PAI-1) deposition in extracellular matrix, which
suggests that PAI-1 is a key factor in mesangial ma-
trix accumulation [14]. The expression of the PAI-1
gene is directly induced by Ang II [15], however, little
is known about the molecular events through which
Ang II induces PAI-1 gene expression in mesangial
cells. With regard to this, the stimulatory e¡ects of
Ang II on collagen and ¢bronectin synthesis have
been reported to be mediated by transforming
growth factor-L (TGF-L) [16,17]. Thus, it is likely
that there is a cross-talk between Ang II and TGF-L
signaling pathways within mesangial cells.
This study was designed to identify the factors in
the Ang II signaling cascade which determines PAI-1
gene expression, and the role of TGF-L in the Ang
II-induced upregulation of PAI-1 expression.
2. Materials and methods
2.1. Cell culture
Rat mesangial cells were prepared as described
previously [18]. Brie£y, kidney cortices were isolated
from 7-week-old male Sprague-Dawley rats. They
were minced and passed through a series of sieves
to isolate the glomeruli. Isolated glomeruli were
treated with 1 mg/ml collagenase (Wako, Osaka, Ja-
pan) for 30 min, resuspended in RPMI-1640 medium
containing 17% fetal bovine serum (Gibco Laborato-
ries, Grand Island, NY), 0.1 U/ml insulin (Sigma
Chemical, St. Louis, MO) and antibiotics, and
seeded in 100 mm plastic tissue culture dishes. Out-
growing mesangial cells were maintained in the same
medium, characterized by an immunohistochemical
staining of desmin, K-smooth muscle actin and cyto-
keratin, and by an uptake of LDL. The cells were
used in experiments at passages 4^7. The expression
of angiotensin II receptor was con¢rmed at each
passage by a 125I-Ang II binding assay.
For Ang II, TGF-L and phorbol 12-myristate 13-
acetate (PMA, Wako) stimulation, cells were ren-
dered quiescent by culturing in serum-free medium
for 24 h, and then stimulated with Ang II (Sigma
Chemical), recombinant human TGF-L1 (Takara,
Tokyo, Japan or Boehringer Mannheim, Tokyo, Ja-
pan) at indicated concentrations for 6 h. In experi-
ments using inhibitors (Calbiochem, La Jolla, CA),
bisindorylmaleimide I, KN-62 and genistein, cells
were pretreated with each inhibitor for 30 min and
then stimulated with Ang II and TGF-L in the pres-
ence of the inhibitor.
In a separate experiment, the e¡ect of PKC down-
regulation on PAI-1 mRNA induction was examined
as follows. To downregulate PKC, cultured mesan-
gial cells were treated with 200 nM PMA for 24 h in
serum-free medium [19]. The cells were then stimu-
lated with Ang II and TGF-L1 for 6 h.
2.2. Angiotensin II binding assay
Rat mesangial cells were seeded in a 24-well cul-
ture plate at a density of 1U105 cells/well. The cells
were incubated in a bu¡er containing 50 mM Tris-
HCl pH 7.5, 2.5 mM MgCl2, 0.1% BSA, 100 WM
bacitracin and 50 pM 125I-Ang II (Amersham Japan,
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Tokyo, Japan) at 37‡C for 1 h. After incubation, the
cells were washed twice with ice-cold phosphate bu¡-
ered saline (PBS) and dissolved in 0.1% SDS in
0.25 N NaOH. The radioactivity of 125I in the lysate
was counted by a gamma counter. Non-speci¢c bind-
ing was determined by processing the cells identical
to above except that 10 WM cold Ang II was initially
added.
2.3. Probe preparation
An 877 bp fragment of rat PAI-1 cDNA and a
476 bp fragment of L-actin cDNA were ampli¢ed
from rat mesangial cell total RNA by the GeneAmp
RNA PCR Kit (Perkin-Elmer, Emeryville, CA). The
sequences of the primers were: rat PAI-1 forward
primer, 345-, AAACCCGGCAGCAGATCCAAG-
A; reverse primer, -1221, GCTGAGACTAGAAT-
GGCTGTGG; rat L-actin forward primer, 954-,
AAAGACCTCTATGCCAACACAGTGC; and re-
verse primer, -1428, GGGATGTTTGCTCCAAC-
CAACTGC. The ampli¢ed fragments were cloned
into TA cloning vector (Invitrogen, San Diego,
CA). Positive clones were con¢rmed by restriction
enzyme mapping and sequencing. Rat PAI-1 and
L-actin cDNA fragments were prepared by digesting
the vectors with EcoRI. The fragments were digox-
igenin (DIG) labeled using DIG High Prime (Boehr-
inger Mannheim) according to the manufacturer’s
instruction.
2.4. Northern blotting
Total RNA was isolated using Isogen (Wako).
One milliliter of Isogen was added to mesangial cells
growing in a 60 mm dish. After cell lysis, the Isogen
was collected in a tube, extracted by chloroform
and centrifuged. RNAs were precipitated with iso-
propanol, rinsed in 75% ethanol and resuspended
in an appropriate amount of diethylpyrocarbonate
(DEPC)-treated water.
Total RNA (10^20 Wg) was fractionated in a 1%
agarose gel by formaldehyde gel electrophoresis. The
RNA was then transferred from the gel to Hybond
N nylon membrane (Amersham Japan) and immo-
bilized by UV cross-linking. The membrane was pre-
hybridized in a solution containing 4USSCP,
1UDenhardt’s, 1% SDS, 50% formamide, 100 Wg/
ml salmon sperm DNA at 42‡C for 3 h. Hybridiza-
tion was performed in a solution containing
4USSCP, 1UDenhardt’s, 1% SDS, 5% dextran sul-
fate, 50% formamide, 100 Wg/ml salmon sperm DNA
and denatured DIG-labeled probe at 42‡C for 16 h.
After hybridization, the membrane was washed twice
with 1USSC, 0.1% SDS at room temperature for
15 min and then washed twice with 0.2USSC, 0.1%
SDS at 42‡C for 15 min. The hybridized probe was
detected using a DIG detection kit (Boehringer
Mannheim) as described in the manufacturer’s in-
struction.
2.5. Measurement of intracellular free calcium
([Ca2+]i)
Rat mesangial cells were trypsinized and washed
twice in PBS containing 0.1% bovine serum albumin
(PBS-0.1% BSA). The cells were incubated in 4 WM
fura-2/AM (Wako) in PBS-0.1% BSA for 30 min at
37‡C, then washed in PBS-0.1% BSA and kept on ice
for 15 min. The cells were resuspended in a bu¡er
containing 5 mM HEPES pH 7.4, 140 mM NaCl,
4 mM KCl, 1 mM MgCl2, 1.25 mM CaCl2, 1 mM
NaH2PO4, 11 mM glucose and 0.1% BSA. About 106
cells were used in each experiment. Fluorescence was
measured with a CAF-100 spectro£uorometer (Japan
Spectroscopy, Tokyo, Japan) with excitation at
340 and 380 nm and emission at 500 nm.
2.6. Western blotting
Quiescent mesangial cells were stimulated with
Ang II and recombinant human TGF-L1 at the in-
dicated concentrations for 16 h in the serum-free
medium containing 0.1% BSA. Then, trichloroacetic
acid was added to the conditioned medium at a ¢nal
concentration of 10% (w/v) and proteins were pre-
cipitated by keeping them on ice for 30 min. Samples
were centrifuged at 14 000Ug for 10 min. Pellets
were washed three times with 500 Wl diethyl ether,
dissolved in Laemmli sample bu¡er, and boiled for
3 min. The mesangial cell monolayer was washed
twice with PBS, lysed in a bu¡er containing 50 mM
Tris-HCl pH 7.5, 150 mM NaCl and 0.5% Triton
X-100. The concentration of cellular lysate was de-
termined by a Bio-Rad protein assay kit (Bio-Rad
Laboratories, Hercules, CA). The amount of the
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sample loading to SDS-PAGE (10% acrylamide) was
corrected by the amount of cellular protein. Proteins
in the conditioned medium were electrophoresed,
transferred to an Immobilon-P membrane (Millipore,
Bedford, MA) and immunoblotted with 2 Wg/ml rab-
bit anti-rat PAI-1 (American Diagnostica, Green-
wich, CT). The signal was developed by the ECL
Western blotting detection system with anti-rabbit
IgG (Amersham) as a second antibody.
2.7. Statistical analysis
Results are presented as means þ S.D. Student’s t-
test was used for comparisons. P6 0.05 was consid-
ered statistically signi¢cant. Each experiment was
performed in at least triplicate.
3. Results
3.1. The role of PKC in Ang II-induced PAI-1 mRNA
upregulation
As reported earlier [20], we con¢rmed that AT1 is
a major Ang II receptor in rat mesangial cells by the
binding assay. AT1 antagonist Dup753 at a concen-
tration of 10 WM inhibited 125I-Ang II binding to
mesangial cells by 99%, whereas the same concentra-
tion of AT2 antagonist PD123319 reduced the value
by only 8%.
A previous report has shown maximal induction of
PAI-1 mRNA expression at 4^8 h of Ang II stimu-
lation at concentrations higher than 100 nM [15]. We
also con¢rmed these ¢ndings (data not shown).
Thus, stimulation with 100 nM Ang II for 6 h was
used for PAI-1 mRNA induction in the present ex-
periments (Fig. 1). Densitometric analysis revealed a
4.6 þ 1.1-fold increase in the expression compared to
the control. Because Ang II signal generates second
messengers, namely intracellular Ca2 and diacylgly-
cerol, we investigated the role of Ca2-dependent
protein kinases in the Ang II-induced PAI-1
mRNA upregulation. Mesangial cells were treated
with a highly speci¢c PKC inhibitor, bisindorylma-
leimide I [21], and a Ca2 calmodulin-dependent pro-
tein kinase II inhibitor, KN-62 [22]. Bisindorylmalei-
mide I inhibited Ang II-induced PAI-1 mRNA
expression in a dose-dependent manner (Fig. 1).
The level of PAI-1 mRNA expression in Ang II-
stimulated cells co-treated with 1 WM bisindorylma-
leimide I was comparable to that in Ang II-non-
treated controls. In contrast, little e¡ect on PAI-1
mRNA expression was observed in the cells treated
with KN-62.
Fig. 1. E¡ect of protein kinase inhibitors on Ang II-induced
PAI-1 mRNA expression. (A) Quiescent mesangial cells were
pretreated with bisindorylmaleimide I (BIM I) or KN-62 for
30 min at the indicated concentrations, and then stimulated
with 100 nM Ang II for 6 h. Total RNA was analyzed by
Northern blotting. Lanes: 1, control, no treatment; 2, Ang II;
3, BIM I 1037 M+Ang II; 4, BIM I 1036 M+Ang II; 5, KN-
62 1036 M+Ang II; 6, KN-62 1035 M+Ang II. (B) Densitomet-
ric analysis of PAI-1 mRNA expression corrected with L-actin
mRNA. *P6 0.05 vs. control; **P6 0.05 vs. Ang II alone.
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To determine the role of PKC in PAI-1 mRNA
induction, mesangial cells were stimulated with a
PKC activator, PMA. PMA induced about 50^70-
fold increase in PAI-1 mRNA expression at a con-
centration of 20 nM (Fig. 2A). In contrast, a calcium
ionophore, ionomycin, even at 1 WM had little e¡ect
on PAI-1 mRNA expression. Moreover, downregu-
lation of PKC prevented the induction of PAI-1
mRNA by Ang II (Fig. 2B). Thus, mesangial cells
pretreated with 200 nM PMA for 24 h failed to in-
duce PAI-1 mRNA by stimulation with Ang II.
These data indicate that PKC is a major signaling
molecule which leads to Ang II-induced PAI-1
mRNA expression.
3.2. Protein tyrosine kinase(s) is involved in
Ang II-induced PAI-1 mRNA upregulation
Ang II has been shown to cause phosphorylation
of multiple protein tyrosine residues [23,24]. To de-
termine whether protein tyrosine kinase(s) is involved
in Ang II-induced PAI-1 mRNA expression, mesan-
gial cells were treated with genistein, which inhibits
protein tyrosine kinases but has little e¡ect on serine
threonine kinases such as PKC [25]. Ang II-induced
PAI-1 mRNA upregulation was completely sup-
pressed by a co-treatment with 100 WM genistein
(Fig. 3A). Genistein also strongly inhibited PMA-in-
duced PAI-1 mRNA upregulation (Fig. 3B).
To further investigate the role for protein tyrosine
kinase(s) in Ang II signaling, we assessed the e¡ect of
genistein on a second messenger, Ca2. Genistein at
a concentration of 100 WM had little e¡ect on the
increase in intracellular free Ca2 level when the cells
were stimulated by Ang II (Fig. 4). Therefore, genis-
tein seems to have little e¡ect on PLC activation
induced by Ang II. These data suggest that at least
one protein tyrosine kinase is working downstream
from PKC in the Ang II signal pathway.
Fig. 2. Role of protein kinase C in PAI-1 mRNA expression.
(A) Quiescent mesangial cells were treated with various concen-
trations of PMA or ionomycin for 6 h. Total RNA was ana-
lyzed by Northern blotting. Lanes: 1, control, no treatment;
2, PMA 20 nM; 3, PMA 200 nM; 4, ionomycin 0.3 WM; 5,
ionomycin 1 WM. (B) Protein kinase C was downregulated by
treatment with 200 nM PMA for 24 h as previously reported
[19]. Then, cells were stimulated with 100 nM Ang II for 6 h.
Total RNA was analyzed by Northern blotting. Left two lanes,
non-PMA treated cells (no PKC downregulation); right two
lanes, PMA treated cells (PKC downregulation). Lanes: 1,
Ang II non-stimulated control ; 2, Ang II stimulated.
Fig. 3. Role of protein tyrosine kinases in Ang II and PMA-in-
duced PAI-1 mRNA expression. (A) Quiescent mesangial cells
were pretreated with 100 WM of genistein for 30 min, and then
stimulated with 100 nM Ang II for 6 h. Total RNA was ana-
lyzed by Northern blotting. (B) Quiescent mesangial cells were
pretreated with 100 WM of genistein for 30 min and then stimu-
lated with 20 nM PMA for 6 h. Lanes: 1, non-treated control;
2, stimulated with Ang II or PMA; 3, genistein+Ang II or
PMA.
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3.3. Association of Ang II and TGF-L signaling in
PAI-1 mRNA upregulation
Ang II has been reported to induce PAI-1 mRNA
expression through a direct action and also through
activation of TGF-L [15]. As shown in Fig. 5A,
TGF-L1 alone induced PAI-1 mRNA expression at
6 h. The induction by 10 ng/ml TGF-L1 signi¢cantly
compared to control non-treated cells (1.6 þ 0.3-fold
induction). The Ang II-induced PAI-1 mRNA ex-
pression was markedly augmented by TGF-L1 (Fig.
5B). Densitometric analysis showed some 2.4 þ 0.2-
fold increase in the cells co-treated with 10 ng/ml
of TGF-L1 and Ang II against the average expres-
sion in cells treated with Ang II alone. These data
indicate a synergistic e¡ect of TGF-L on Ang II-in-
duced PAI-1 mRNA expression. Thus TGF-L super-
induced PAI-1 mRNA expression in the presence of
Ang II to a higher extent than in its absence.
To determine the site of Ang II and TGF-L1 syn-
ergism, the role of PKC and protein tyrosine kinase
was investigated. The PKC inhibitor, bisindorylma-
leimide I, and the protein tyrosine kinase inhibitor,
genistein, completely inhibited TGF-L-dependent
superinduction of Ang II-induced upregulation of
PAI-1 mRNA (Fig. 6). Thus, the densities of the
mRNA in bisindorylmaleimide I- or genistein-treated
cells were not di¡erent from those in the control
(Ang II-non-stimulation) cells. These data indicate
that PKC and protein tyrosine kinase(s) are involved
in PAI-1 mRNA upregulation even in the presence of
both Ang II and TGF-L.
The role of PKC in the TGF-L-dependent super-
induction of Ang II-induced PAI-1 mRNA expres-
sion was further examined by PMA. TGF-L1 super-
induced PMA-induced PAI-1 mRNA expression in a
dose dependent manner (Fig. 7A). Moreover, down-
regulation of PKC by the pretreatment with PMA
Fig. 4. The e¡ect of genistein on Ang II-stimulated elevation of
intracellular free calcium ([Ca2]i). Mesangial cells were loaded
with Fura 2 and pretreated with 100 WM of genistein for 30
min. The cells were then stimulated with 100 nM Ang II.
Upper panel, genistein non-treated control; lower panel, genis-
tein treated.
Fig. 5. TGF-L synergistically increases Ang II-induced PAI-1
mRNA expression. Quiescent mesangial cells were stimulated in
the presence or absence of 100 nM Ang II with various concen-
trations of human recombinant TGF-L1 for 6 h. (A) Stimula-
tion with TGF-L alone. (B) Stimulation with TGF-L and Ang
II. Lanes: 1, TGF-L non-stimulated control; 2, TGF-L 0.1 ng/
ml; 3, TGF-L 1 ng/ml; 4, TGF-L 10 ng/ml. Note that accord-
ing to a rather weak signal of control, the panel A PAI-1
mRNA blot was developed by 5 times longer exposure to an
X-ray ¢lm.
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prevented TGF-L-dependent superinduction of Ang
II-induced PAI-1 mRNA expression to the level
comparable to TGF-L1 alone (Fig. 7B). These data
suggest that Ang II and TGF-L1 synergism occurs
downstream from PKC.
Finally, we determined the e¡ect of Ang II and
TGF-L on PAI-1 protein expression. In accordance
with the results of Northern blot analysis, Ang II
and TGF-L induced PAI-1 protein expression, and
a synergistic e¡ect of Ang II and TGF-L was ob-
served by the Western blot analysis (Fig. 8). These
data are comparable to the data of Northern blot
analysis.
Fig. 6. Role of PKC and protein tyrosine kinases in PAI-1
mRNA superinduction by TGF-L and Ang II. (A) Quiescent
mesangial cells were pretreated with 1 WM of bisindorylmalei-
mide I (BIM I) or 100 WM of genistein for 30 min, and then
stimulated with 100 nM Ang II and/or 10 ng/ml of human re-
combinant TGF-L1 for 6 h. Total RNA was analyzed by
Northern blotting. Lanes: 1, non-treated control; 2, TGF-L
alone; 3, Ang II alone; 4, Ang II+TGF-L ; 5, treated with BIM
I and stimulated with Ang II+TGF-L ; 6, treated with genistein
and stimulated with Ang II+TGF-L. (B) Densitometric analysis
of PAI-1 mRNA expression corrected with L-actin mRNA.
*P6 0.05 vs. control; **P6 0.05 vs. Ang II and TGF-L ;
#P6 0.05 vs. Ang II, TGF-L and Ang II+TGF-L.
Fig. 7. Role of protein kinase C in TGF-L-induced PAI-1
mRNA expression. (A) Quiescent mesangial cells were treated
with various concentrations of human recombinant TGF-L1
plus 20 nM PMA for 6 h. Total RNA was analyzed by North-
ern blotting. Lanes: 1, TGF-L non-stimulated control; 2, TGF-
L 0.1 ng/ml; 3, TGF-L 1 ng/ml; 4, TGF-L 10 ng/ml. (B) Protein
kinase C was downregulated by treatment with 200 nM PMA
for 24 h as previously reported [19]. Then, cells were stimulated
with 100 nM Ang II and 10 ng/ml TGF-L1 for 6 h. Total
RNA was analyzed by Northern blotting. Left three lanes, non-
PMA treated cells (no PKC downregulation). Lanes: 1, non-
stimulated control; 2, TGF-L alone; 3, Ang II and TGF-L
stimulated. Right two lanes, PMA treated cells (PKC downre-
gulation). Lanes: 1, TGF-L alone; 2, Ang II and TGF-L stimu-
lated.
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4. Discussion
The present study con¢rmed that angiotensin II
upregulates PAI-1 gene expression in glomerular me-
sangial cells. The receptor binding study showed that
cultured rat mesangial cells expressed mostly type 1
Ang II receptor. Binding of Ang II to AT1 has been
shown to evoke phospholipase C activation, leading
to the generation of inositol triphosphate and diac-
ylglycerol in mesangial cells [26]. These second mes-
sengers have been proposed to induce elevation of
intracellular Ca2 and activation of PKC; however,
the signals that eventually regulate the gene expres-
sion have not been identi¢ed. The results of the
present study using a speci¢c inhibitor, bisindorylma-
leimide I, suggest that PKC is a key molecule in Ang
II signaling that leads to PAI-1 mRNA upregulation.
The role of PKC was further con¢rmed in the cells in
which PKC was downregulated. In the PKC down-
regulated cells, Ang II showed little PAI-1 mRNA
induction. Thus, Ang II activates PKC to further
trigger a signal cascade that leads to PAI-1 mRNA
upregulation.
Our results of experiments with genistein demon-
strated that Ang II mediated PAI-1 mRNA induc-
tion is inhibited by this tyrosine kinase inhibitor.
This inhibition by genistein suggests that protein ty-
rosine kinase(s) is another key factor that partici-
pates in Ang II signaling downstream from PKC in
the cascade. PKC phosphorylates many proteins in
vitro, including signal transduction proteins such as
c-Src [27], c-Abl [28] and c-Raf [29]. c-Src and c-Abl
have protein tyrosine kinase activity and c-Raf acti-
vates the MAP kinase cascade. Ang II has been
shown to increase tyrosine kinase activity of c-Src
and tyrosine phosphorylation of the mitogen-acti-
vated protein (MAP) kinases in cultured rat smooth
muscle cells [30]. Thus, the Ang II-induced PKC ac-
tivation in the present experimental conditions may
cause phosphorylation of these proteins.
TGF-L has been shown to induce PAI-1 mRNA
expression in a variety of cells including human me-
sangial cells and bovine vascular smooth muscle cells
[31,32]. In the present study, TGF-L enhanced the
expression of PAI-1 mRNA in rat mesangial cells.
TGF-L further superinduced Ang II-induced PAI-1
mRNA expression. Thus synergism of Ang II and
TGF-L was observed.
Ang II has been implicated to mediate extracellu-
lar matrix accumulation in glomerular injury [6].
TGF-L has also been proposed to be a key patho-
genic factor in progressive glomerular diseases, yet,
molecular interactions between Ang II and TGF-L
signaling systems have not been well characterized.
In an experimental animal model, injection of anti-
TGF-L antibody ameliorated extracellular matrix ex-
pansion [33]. In human, enhanced expression of
TGF-L in glomeruli was observed in many glomer-
ular diseases [34]. In serum-free conditions, we dem-
onstrated that TGF-L superinduces Ang II-induced
PAI-1 mRNA upregulation. Thus, the present study
suggests that TGF-L acts synergistically with a lo-
cally activated renin-angiotensin system to induce
PAI-1 expression. By interacting with plasminogen
activators, PAI-1 inhibits the generation of a pro-
tease, plasmin. Plasmin plays a key role in mesangial
matrix turnover not only by degrading matrix pro-
teins but also by activating matrix metalloproteases
[14]. The Ang II and TGF-L-induced PAI-1 upregu-
lation thus may contribute to glomerular matrix ac-
cumulation.
The site of molecular interaction between Ang II
and TGF-L signaling pathways was explored in the
present study. We showed that PKC-dependent path-
way and protein tyrosine kinase action downstream
from PKC are essential to Ang II-induced PAI-1
expression even when TGF-L is added to the system.
Thus, a PKC inhibitor, bisindorylmaleimide I, and a
protein tyrosine kinase inhibitor, genistein, attenu-
ated the TGF-L e¡ect on Ang II-induced PAI-1
mRNA upregulation. TGF-L enhanced PAI-1
mRNA expression induced by PMA, and a down-
regulation of PKC prevented TGF-L-dependent
superinduction of Ang II-induced PAI-1 mRNA ex-
Fig. 8. E¡ect of Ang II and TGF-L on PAI-1 protein expres-
sion. Quiescent mesangial cells were stimulated with 100 nM
Ang II and 10 ng/ml TGF-L1 for 16 h. Extracellular protein
was precipitated with trichloroacetic acid and analyzed by
Western blotting with anti-rat PAI-1 antibody. The amount of
the sample loading was corrected by the amount of cellular
protein. Lanes: 1, non-treated control; 2, TGF-L alone; 3, Ang
II; 4, Ang II+TGF-L.
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pression to the level comparable to TGF-L1 alone.
Although not conclusive, these results indicate that
the synergistic interaction takes place downstream
from PKC. Several mechanisms for the interaction
can be postulated. Ang II induces PAI-1 expression
at the transcriptional level [15]. PMA, a PKC activa-
tor, is well known to regulate many gene expressions
through phorbol ester responsive elements (TRE).
The promoter region of PAI-1 gene has two TRE-
like elements and these elements have been shown to
respond to PMA in other cell types [35,36]. Thus,
Ang II-induced PKC activation may result in tran-
scriptional activation by TRE. The presence of a
TGF-L responsive element in the PAI-1 gene pro-
moter region has also been reported [37] and Smads,
transcription factors activated by TGF-L, have been
shown to bind to this region [38]. Thus, it is possible
that the TGF-L responsive element and the TRE
element interact to enhance PAI-1 gene expression.
Another possible mechanism of the interaction is the
presence of a common factor in the Ang II and
TGF-L signaling cascades. Recently, a member of
MAPKKK, designated TAK1, was identi¢ed as a
mediator of the TGF-L signaling pathway. An acti-
vator of TAK1, TAB1, in the pathway has also been
cloned [39]. Overexpression of TAB1 in Mv1Lu cells
results in an enhanced PAI-1 gene promoter activity.
Members of MAPK may be the site of cross-talk
between Ang II and TGF-L signaling.
Overall, our results indicate that a locally activated
renin-angiotensin system and TGF-L may synergisti-
cally induce PAI-1, which, in turn, may cause glo-
merular extracellular matrix accumulation to pro-
mote glomerular injury. Previous therapeutic
interventions aimed to regulate the Ang II and
TGF-L pathways separately. The present work
evoked a possible new target to regulate both Ang
II and TGF-L signal pathways.
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